Home | Business News | Browse by Publication | P | PR Newswire

Positive Phase I Data for Neurotech's NT- 501 Encapsulated Cell Delivery of Ciliary Neurotrophic Factor to Eyes of Patients With Retinitis Pigmentosa.

Article Excerpt
Data Presented at the 77th Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) Conference in Fort Lauderdale, Florida

FORT LAUDERDALE, Florida, May 1 /PRNewswire/ -- Neurotech SA, a specialist in the development of novel therapies for retinal diseases, today announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech's patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Results confirm that CNTF can be safely delivered into the vitreous of patients with RP and that the ECT device was well tolerated by all patients. Futhermore, some patients experienced more than one-line of improvement in their visual acuity score. These Phase I results were presented at the ARVO annual meeting and the trial was conducted at the National Eye Institute (NEI), Bethesda, USA. Neurotech has confirmed that it will now progress to a multi-center Phase II trial.

ECT, a technique developed and patented by Neurotech, allows for genetically-engineered specific protein delivery without manipulating the patient's genetic information or transferring new genetic...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!